{"schema_version":"secwatch.filing_event.v1","accession":"0001448431-26-000009","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2026-05-12T20:07:01+00:00","discovered_at":"2026-05-12T20:08:00.302384+00:00","generated_at":"2026-05-12T21:26:05.785680+00:00","sec_items":["1.01","1.02","2.02","2.03","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"OptimizeRx Q1 rev $19.8M, adj EBITDA $3.3M; guides FY rev $95-100M, refi saves $1.5M","bullets":["Q1 revenue $19.8M (down 10% YoY), GAAP net loss $(0.5)M ($(0.03)/share) vs $(2.2)M loss a year ago.","Non-GAAP net income $2.7M ($0.14/diluted), adjusted EBITDA $3.3M vs $1.5M prior year.","FY 2026 revenue guidance updated to $95-100M; adjusted EBITDA guidance unchanged $21-25M.","Refinanced debt with Fifth Third Bank: $25M term loan + $10M revolver, annual interest savings ~$1.5M.","Launched efficiency initiatives expected to save $3M annually, including $1M in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001448431-26-000009","json":"https://secwatch.observer/filing/0001448431-26-000009.json","markdown":"https://secwatch.observer/filing/0001448431-26-000009.md","text":"https://secwatch.observer/filing/0001448431-26-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000144843126000009/0001448431-26-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000144843126000009/oprx-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:26:05.785680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25fb6d5f3d533286978f9c6c61570e3a9bb17416","claim":"OptimizeRx Corp incurred credit facility of $35.0 million with Fifth Third Bank, National Association at Base Rate or Term SOFR plus an applicable margin ranging from 0.75% to 1.50% for maturing May 7, 2031.","evidence_excerpt":"Lead Arranger and Sole Bookrunner in connection with the Credit Agreement. The Credit Agreement provides for senior secured credit facilities in an aggregate principal amount of $35.0 million on the Closing Date, consisting of (i) a $10.0 million revolving credit facility (the “Revolving Facility”), which includes a $250,000 letter of credit subfacility and a swing","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000144843126000009/0001448431-26-000009-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$35.0 million"},{"label":"Counterparty","value":"Fifth Third Bank, National Association"},{"label":"Rate","value":"Base Rate or Term SOFR plus an applicable margin ranging from 0.75% to 1.50% for"},{"label":"Maturity","value":"May 7, 2031"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"eaa56d33d3592f776046656bf5029c08479e0210","claim":"OptimizeRx Corp reported first quarter ended March 31, 2026 results: revenue $19.8 million, net income $(0.5) million, EPS $(0.03) per share. Guidance reaffirmed.","evidence_excerpt":"specific reference in such filing. --- EX-99.1 (EX-99.1) --- OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Q1 revenue totals $19.8 million - Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively - 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000144843126000009/0001448431-26-000009-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$19.8 million"},{"label":"Net income","value":"$(0.5) million"},{"label":"EPS","value":"$(0.03) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"639455cb2fadc3d216429c746a4d3b450e8b2137","claim":"OptimizeRx Corp terminated Existing Term Loan with Blue Torch Finance, LLC (effective 2026-05-07).","evidence_excerpt":"On the Closing Date, the Company terminated and repaid in full all obligations outstanding under the Existing Term Loan with the proceeds from the new Term Loan.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000144843126000009/0001448431-26-000009-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Blue Torch Finance, LLC"},{"label":"Effective","value":"2026-05-07"}],"fact_type":"material_agreement"},{"claim_id":"b912d65ea13907bdee1d6ccaeab335cc22d0991e","claim":"OptimizeRx Corp entered into Credit Agreement with Fifth Third Bank, National Association valued at $35.0 million (effective 2026-05-07).","evidence_excerpt":"On May 7, 2026 (the “Closing Date”), OptimizeRx Corporation, a Nevada corporation (the “Company” or “Borrower”), entered into a credit agreement (the “Credit Agreement”) with the other loan parties from time to time party thereto (the “Loan Parties”), the lenders from time to time party thereto (the “Lenders”), and Fifth Third Bank, National Association (“Fifth Third”), as Agent, L/C Issuer and Swing Line Lender.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000144843126000009/0001448431-26-000009-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Fifth Third Bank, National Association"},{"label":"Value","value":"$35.0 million"},{"label":"Effective","value":"2026-05-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}